In the light of recent clinical trial results, there was much for clinicians and researchers at EAS 2023 (21-24 May, Mannheim, Germany), to debate about the role of triglycerides as a marker of cardiovascular risk or a target for treatment, as well as the importance of reducing apoB-containing particles. In addition, there were updates on studies of evinacumab, pemafibrate and vupanorsen and initial findings with the investigational RNAi therapeutic, ARO-ANG3.
Read the reports:
- Triglycerides and CVD: Where do we stand?
- Evinacumab reduces need for apheresis
- Pemafibrate effects in fatty liver disease
- ARO-ANG3 compares favourably with ANGPTL3 mAbs in HoFH
- New insights on increased liver fat fraction with ANGPTL3 silencing
Reportage by Jenny Bryan